Welcome, Guest. Please login or register.
April 23, 2024, 01:52:32 am

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 33
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 19
Total: 19

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: post hep c tests  (Read 6655 times)

0 Members and 1 Guest are viewing this topic.

Offline trapper

  • Member
  • Posts: 56
post hep c tests
« on: February 05, 2016, 01:28:45 pm »
june 2015 was 12 post hcv test witch was good.  hcv gone.  how long after do they want you to get a scan or biopsy to ck  liver for cancer or whatever and whats the best test to get.  I was f-3 prior to treatment. thanks  trapper

Offline gnatcatcher

  • Member
  • Posts: 1,372
Re: post hep c tests
« Reply #1 on: February 05, 2016, 01:47:58 pm »
Every doctor seems to have a different idea of when, what, and how often to test. My hepatologist was going to do an SVR36 rather than an SVR24, but since my PCP would be doing labs at around the SVR24 date, the hepatologist decided just to have my PCP test my viral load then. Then he wants an annual viral load (plus a hepatic panel, which my PCP does annually anyway) for 3 years. If my next FibroScan (in late June) still shows F4, the hepatologist wants me to keep having ultrasounds and hepatology follow-ups every six months. If I revert to F3, he's going to let my PCP handle things from then on out.

Congratulations on eradicating the HCV. Please let us know what further tests your doctor orders.

Gnatty
9/29/71 transfusions
HCV genotype 1a
7/09/15-9/30/15 Harvoni

Before treatment:
Viral Load 9,490,582
FibroScan 19.5 kPa [F4]
ALT 262
AST 217
ALP 183

Most recent:
VL still UNDETECTED (SVR 102)
FibroScan 7.6 kPa [F1-2]
ALT 15
AST 20
ALP 85

Offline Lynn K

  • Global Moderator
  • Member
  • Posts: 4,544
  • Get tested, get treated, get cured, fight Hep c!
Re: post hep c tests
« Reply #2 on: February 06, 2016, 02:33:42 am »
For me as a F4 cirrhosis patient I am to have Abdominal ultrasound and Alpha fetoprotein (AFP) blood testing every 6 months to monitor for possible HCC I will likely have this done for life.

I will also have annual upper endoscopies to check for recurrence of esophageal varicies. I developed grade 3 varicies the required banding back in 2012 so I am checked to make sure they don't come back.

I am having my one year follow up soon post treatment and asked to do a HCV RNA by PCR test for my own peace of mind. I doubt I will do any more testing for the virus after that.

I found this on the AASLD (American Association for the Study of Liver Disease) web site.

http://www.hcvguidelines.org/full-report/monitoring-box-summary-recommendations-monitoring-patients-who-are-starting-hcv

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Summary of the Recommendations for Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

Recommended follow-up for patients who achieve a sustained virologic response (SVR).

For patients who do not have advanced fibrosis (ie, those with Metavir stage F0-F2), recommended follow-up is the same as if they were never infected with HCV.

Rating: Class I, Level B

Assessment for HCV recurrence or reinfection is recommended only if the patient has ongoing risk for HCV infection or otherwise unexplained hepatic dysfunction develops. In such cases, a quantitative HCV RNA assay rather than an anti-HCV serology test is recommended to test for HCV recurrence or reinfection.

Rating: Class I, Level A

Surveillance for hepatocellular carcinoma with twice-yearly ultrasound testing is recommended for patients with advanced fibrosis (ie, Metavir stage F3 or F4) who achieve an SVR.

Rating: Class I, Level C

A baseline endoscopy is recommended to screen for varices if cirrhosis is present. Patients in whom varices are found should be treated and followed up as indicated.

Rating: Class I, Level C

Assessment of other causes of liver disease is recommended for patients who develop persistently abnormal liver tests after achieving an SVR.


In more detail

With the advent of highly effective HCV antiviral regimens, the likelihood of achieving an SVR among adherent, immunologically competent, treatment-naive patients with compensated liver disease generally exceeds 90%. Of patients who achieved an SVR with PEG-IFN  and RBV treatment, more than 99% have remained free of HCV infection when followed up for 5 years after completing treatment. (Manns, 2013) Thus, achieving an SVR is considered a virologic cure of HCV infection.

SVR typically aborts progression of liver injury with regression of liver fibrosis in most but not all treated patients. (Morisco, 2013); (Morgan, 2010); (George, 2009); (Morgan, 2013); (Singal, 2010) Because of lack of progression, patients without advanced liver fibrosis (ie, Metavir stage F0-F2) who achieve an SVR should receive standard medical care that is recommended for patients who were never infected with HCV.

Among patients with advanced liver fibrosis (ie, Metavir stage F3 or F4) who achieve an SVR, decompensated liver disease (with the exception of hepatocellular carcinoma) rarely develops during follow-up, and overall survival is prolonged. (Morisco, 2013); (Morgan, 2010); (George, 2009); (Morgan, 2013); (Singal, 2010) Patients who have advanced fibrosis or cirrhosis continue to be at risk for development of hepatocellular carcinoma after achieving an SVR, although the risk in these patients is lower than the risk in persistently viremic patients. (Morisco, 2013); (Morgan, 2010); (George, 2009); (Morgan, 2013); (Singal, 2010) Patients with cirrhosis who achieve SVR experience increased survival (compared with patients with cirrhosis who are untreated or in whom treatment fails), but still may be at some risk for hepatocellular carcinoma; thus, they should continue to undergo regular surveillance for hepatocellular carcinoma despite the lowered risk that results after viral eradication. (Bruix, 2011) The risk of hepatocellular carcinoma among patients with advanced fibrosis prior to treatment but who have regression to minimal fibrosis after treatment is not known. In the absence of data to the contrary, such patients remain at some risk for hepatocellular carcinoma and should be monitored at regular intervals for hepatocellular carcinoma.

Liver fibrosis and liver function test results improve in most patients who achieve an SVR. (Morisco, 2013); (Morgan, 2010); (George, 2009); (Morgan, 2013); (Singal, 2010) Bleeding from esophageal varices is rare after an SVR. (Morisco, 2013); (Morgan, 2010); (George, 2009); (Morgan, 2013); (Singal, 2010) Patients with cirrhosis should receive routine surveillance endoscopy for detection of esophageal varices if not previously done and these should be treated or followed up as indicated. (Garcia-Tsao, 2007)

Patients in whom an SVR is achieved but who have another potential cause of liver disease (eg, excessive alcohol use, metabolic syndrome with or without proven fatty liver disease, or iron overload) remain at risk for progression of fibrosis. It is recommended that such patients be educated about the risk of liver disease and monitored for liver disease progression with periodic physical examinations, blood tests, and potentially, tests of liver fibrosis by a liver disease specialist.

Periodically testing patients with ongoing risk for HCV infection (eg, illicit drug use, high-risk sexual exposure) for HCV reinfection is recommended. Flares in liver enzyme test results should prompt evaluation of possible de novo reinfection with HCV through a new exposure (see Management of Acute HCV Infection). Antibody to HCV (anti-HCV) remains positive in most patients following an SVR. Thus, testing for reinfection with HCV is recommended and should be performed with an assay that detects HCV RNA (eg, a quantitative HCV RNA test).
« Last Edit: February 06, 2016, 02:36:42 am by Lynn K »
Genotype 1a
1978 contracted, 1990 Dx
1995 Intron A failed
2001 Interferon Riba null response
2003 Pegintron Riba trial med null response
2008 F4 Cirrhosis Bx
2014 12 week Sov/Oly relapse
10/14 fibroscan 27 PLT 96
2014 24 weeks Harvoni 15 weeks Riba
5/4/15 EOT not detected, ALT 21, AST 20
4 week post not detected, ALT 26, AST 28
12 week post NOT DETECTED (07/27/15)
ALT 29, AST 27 PLT 92
24 week post NOT DETECTED! (10/19/15)
44 weeks (3/11/16)  fibroscan 33, PLT 111, HCV NOT DETECTED!
I AM FREE!

Offline trapper

  • Member
  • Posts: 56
Re: post hep c tests
« Reply #3 on: February 07, 2016, 05:16:55 pm »
thanks knatty and lynn.  the info answers my questions. thanks   trapper

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.